Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Piaserico, S; Osto, E; Famoso, G; Zanetti, I; Gregori, D; Poretto, A; Iliceto, S; Peserico, A; Tona, F.
Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
Atherosclerosis. 2016; 251:25-30 Doi: 10.1016/j.atherosclerosis.2016.05.036
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Osto Elena
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND AND AIMS: In patients with psoriasis, the chronic exposure to systemic inflammation can result in coronary microvascular dysfunction (CMD). In this self-controlled, prospective pilot study, we investigated whether a long-term treatment with TNF-α inhibitors effective against skin symptoms also improves coronary flow reserve in psoriasis patients (CFR). METHODS: We prospectively studied 37 consecutive psoriasis patients (31 male; age, 37.7 ± 8.5 years) without cardiovascular disease, before and after anti-TNF-α treatment. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. A CFR≤2.5 was considered a marker of CMD. Psoriasis was assessed by Psoriasis Area and Severity Index (PASI). High sensitive C-reactive protein (hs-CRP) and serum TNF-α were assessed. RESULTS: Overall, CFR increased from 2.2 ± 0.7 to 3.02 ± 0.8 (p < 0.0001) after TNF-α inhibitors therapy. In patients with CMD, CFR increased from 1.88 ± 0.3 to 2.74 ± 0.5 (p < 0.0001). In patients with normal CFR, CFR increased from 3.0 ± 0.5 to 3.7 ± 0.9 (p = 0.08). CFR improvement after TNF-α inhibitors treatment was correlated with hs-CRP and TNF-α reduction (p = 0.004 and p = 0.02, respectively), but not with change in PASI (p = 0.5). CONCLUSIONS: The present study demonstrates that TNF-α inhibitors treatment ameliorates CMD in patients with established psoriasis not responding to long-term conventional therapy. These findings suggest that a therapy specifically targeted against inflammation is able to positively affect coronary microvascular function.
Find related publications in this database (using NLM MeSH Indexing)
Adalimumab - therapeutic use
Adult - administration & dosage
C-Reactive Protein - analysis
Chronic Disease - administration & dosage
Coronary Angiography - administration & dosage
Coronary Circulation - drug effects
Coronary Vessels - physiopathology
Echocardiography, Doppler - administration & dosage
Etanercept - therapeutic use
Female - administration & dosage
Fractional Flow Reserve, Myocardial - administration & dosage
Humans - administration & dosage
Inflammation - blood, drug therapy
Infliximab - therapeutic use
Male - administration & dosage
Microcirculation - drug effects
Middle Aged - administration & dosage
Multivariate Analysis - administration & dosage
Pilot Projects - administration & dosage
Prospective Studies - administration & dosage
Psoriasis - blood, drug therapy, physiopathology
Tumor Necrosis Factor-alpha - antagonists & inhibitors, blood

Find related publications in this database (Keywords)
Coronary flow reserve
Coronary microcirculation
Inflammation
Risk factors
Psoriasis
© Med Uni Graz • Impressum